Evidence map›Paper›PMID 38550694›Full record

ArticleChemical science2024

Discovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia.

Yunkai Shi, Minmin Liu, Mengna Li, Yiwen Mao, Jingkun Ma, Ruikai Long, Miaomiao Xu, Yaxi Yang, Wenlong Wang, Yubo Zhou and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Targeted degradation of Pin1 by protein-destabilizing compounds.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Yunkai ShiSchool of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China zhoubing2012@hotmail.com.ORCID https://orcid.org/0009-0003-0694-2461
Minmin LiuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 555 Zu Chong Zhi Road Shanghai 201203 China ybzhou@simm.ac.cn jli@simm.ac.cn zhoubing@simm.ac.cn.
Mengna LiSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine Nanjing 210023 China.
Yiwen MaoSchool of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China zhoubing2012@hotmail.com.
Jingkun MaState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 555 Zu Chong Zhi Road Shanghai 201203 China ybzhou@simm.ac.cn jli@simm.ac.cn zhoubing@simm.ac.cn.
Ruikai LongSchool of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China zhoubing2012@hotmail.com.
Miaomiao XuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 555 Zu Chong Zhi Road Shanghai 201203 China ybzhou@simm.ac.cn jli@simm.ac.cn zhoubing@simm.ac.cn.
Yaxi YangSchool of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China zhoubing2012@hotmail.com.
Wenlong WangSchool of Pharmaceutical Science, Jiangnan University Wuxi 214122 China wenlongwang@jiangnan.edu.cn.
Yubo ZhouSchool of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China zhoubing2012@hotmail.com.
Jia LiSchool of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China zhoubing2012@hotmail.com.
Bing ZhouSchool of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China zhoubing2012@hotmail.com.ORCID https://orcid.org/0000-0003-1813-8035
Nanjing University of Chinese Medicine · CNChinese Academy of Sciences · CNInstitute for Advanced Study · DEJiangnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptidyl-prolyl

Identifiers

PMID38550694
PMCPMC10967256
OpenAlexW4392251288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.